Genetic deletion of PCAF exacerbated stress-induced cardiac hypertrophy and increased mortality to 47% compared to 10% in wild-type mice, while pharmacological activation with SPV106 preserved function.
Does PCAF deficiency exacerbate stress-induced cardiac remodeling and dysfunction in mouse models?
8-week-old male C57BL/6J mice (global PCAF-knockout and cardiomyocyte-specific conditional KO models) subjected to isoproterenol infusion or transverse aortic constriction (TAC). Also includes human transcriptomic data from 7 dilated cardiomyopathy (DCM) patients and 5 healthy donors.
Genetic ablation of PCAF (global or cardiomyocyte-specific) and pharmacological activation of PCAF with SPV106.
Wild-type (WT) or flox/flox littermate control mice subjected to the same pathological stress (isoproterenol or TAC).
Cardiac remodeling and dysfunction assessed by echocardiography (ejection fraction, fractional shortening), histological analysis (hypertrophy, fibrosis), and survival.surrogate
PCAF protects against stress-induced cardiac remodeling by activating the CAMKK2-AMPK signaling axis, highlighting its potential as a therapeutic target for heart failure.
Absolute Event Rate: 47% vs 10%
p-value: p=<0.05
Abstract Here we aim to elucidate the role of the p300/CBP-associated factor (PCAF) in pathological cardiac remodeling. Specifically, we explore how PCAF-mediated acetylation of calcium/calmodulin-dependent protein kinase kinase 2 (CAMKK2) influences AMPK signaling, thereby regulating cardiac hypertrophy and dysfunction under pathological stress. A genetically engineered PCAF-knockout (KO) mouse model was generated using the CRISPR–Cas9 system to evaluate the effect of PCAF deficiency on cardiac remodeling induced by isoproterenol infusion and transverse aortic constriction (TAC). PCAF deficiency significantly aggravated cardiac enlargement with features of eccentric hypertrophy, as demonstrated by histological analysis and echocardiography. To determine these phenotypes were cardiomyocyte specific, we generated a cardiomyocyte-specific conditional KO model, which also showed a dilated cardiomyopathy-like phenotype similar to that of the global-KO mice. Transcriptomic analysis of TAC-operated hearts from wild-type and KO mice revealed enrichment of pathways related to mitochondrial function and energy homeostasis. Mechanistically, PCAF directly acetylated CAMKK2, promoting its activation and the subsequent phosphorylation of AMP-activated protein kinase α (AMPKα) at Thr172, a critical step in maintaining metabolic balance under stresses. These signaling alterations were also observed in the hearts of PCAF-KO hearts subjected to isoproterenol administration or TAC. Pharmacological activation of PCAF with SPV106 effectively attenuated TAC-induced cardiac remodeling, preserving cardiac structure and function. Collectively, these findings identify PCAF as a pivotal regulator of pathological cardiac remodeling through modulation of the CAMKK2–AMPK signaling axis. Loss of PCAF exacerbates stress-induced cardiac hypertrophy and dysfunction, highlighting its potential as a therapeutic target to preserve cardiac function and counteract stress-induced remodeling.
Building similarity graph...
Analyzing shared references across papers
Loading...
Yongwoon Lim
Anna Jeong
Duk‐Hwa Kwon
Experimental & Molecular Medicine
Building similarity graph...
Analyzing shared references across papers
Loading...
Lim et al. (Mon,) conducted a other in Cardiac remodeling and hypertrophy. PCAF knockout and SPV106 (PCAF activator) vs. Wild-type mice or vehicle was evaluated on Mortality rate after 4 weeks of transverse aortic constriction (TAC) (p=<0.05). Genetic deletion of PCAF exacerbated stress-induced cardiac hypertrophy and increased mortality to 47% compared to 10% in wild-type mice, while pharmacological activation with SPV106 preserved function.
synapsesocial.com/papers/69e713decb99343efc98d50a — DOI: https://doi.org/10.1038/s12276-026-01698-z